Actively Recruiting
Phase II Study Comparing AZD0292 to Placebo for Prevention of Lung Exacerbations in Chinese Adults with Bronchiectasis and Chronic Pseudomonas Aeruginosa Infection
Led by AstraZeneca · Updated on 2026-10-08
84
Participants Needed
40
Research Sites
20 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase II study focuses on Chinese adults with non-cystic fibrosis bronchiectasis and frequent lung flare-ups due to persistent PsA infection, which affects lung function, quality of life, and survival. Participants receive either AZD0292 or a placebo administered intravenously starting on Day 1, with additional doses given according to the study schedule. The trial compares the safety, effectiveness, and how the body processes AZD0292 versus placebo over a treatment period lasting between 28 and 52 weeks. Throughout the study, participants undergo regular assessments including lung function tests, quality of life questionnaires, and blood tests to measure drug levels and immune responses. Researchers monitor the number of lung exacerbations and any adverse events during treatment and for up to 24 weeks after the last dose. The total participation period can extend beyond one year to capture these outcomes and ensure participant safety.
CONDITIONS
Brief Title
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here